Significance of KRAS mutation in patients receiving mF0LF0X6 with or without bevacizumab for metastatic colorectal cancer

Hepato-Gastroenterology

Volumn 61, Issue 136, 2014, Pages 2222-2226

  Koike, Junichi ^a   Ushigome, Mitsunori ^a   Funahashi, Kimihiko ^a   Shiokawa, Hiroyuki ^a   Kaneko, Tomoaki ^a   Arai, Kenichiro ^a   Matsuda, Satoshi ^a   Kagami, Satoru ^a   Suzuki, Takayuki ^a   Kurihara, Akiharu ^a   Shimada, Hideaki ^a   Kaneko, Hironori ^a  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bevacizumab; Colorectal Cancer; KRAS; MFOLFOX6

Indexed keywords

BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; FOLINIC ACID; K RAS PROTEIN; OXALIPLATIN; ANTINEOPLASTIC AGENT; KRAS PROTEIN, HUMAN; MONOCLONAL ANTIBODY; ONCOPROTEIN; PLATINUM COMPLEX; RAS PROTEIN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; MALE; METASTATIC COLORECTAL CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; WILD TYPE; COLORECTAL NEOPLASMS; GENETICS; METASTASIS; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RETROSPECTIVE STUDIES;

EID: 84921784091     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge14756     Document Type: Article

References (20)

1. Barbacid M: Ras genes. Ann Rev Biochem 1987, 56 779-827.
2. Losi L, Benhattar J, Costa J Stability of K-ras mutations throughout the natural history of human colorectal cancer bur J Cancer 1992, 28A. 1115-1120
3. Suchy B, Zietz C, Rabes HM: K-ras point mutations in human colorectal carcinomas relation to aneuploidy and metastasis Int J Cancer 1992; 52-30-33
4. Dix BR, Robbins P, Soong R., et al.: The common molecular genetic alterations in Dukes' B and C colorectal carcinomas are not short-term prognostic indicators of survival Int J Cancer 1994; 59. 747-751
5. Boguski MS, McCormick F: Proteins regulating Ras and its relatives. Nature 1993, 366, 643-654.
6. Chang F, Steelman LS, Lee J.T., et al.: Signal transduction mediated by the Ras/Rat/MEK/ERK pathway from cytokine receptors to transcription factors, potential targeting for therapeutic intervention Leukemia 2003, 17 1263-1293
7. Mebratu Y, Tesfaigzi Y: How ERK1/2 activation controls cell proliferation and cell death Is subcellular localization the answer? Cell Cycle 2009; 8 1168-1175
8. Gollob JA, Wilhelm S, Carter C., et al.: Role of Raf kinase in cancer therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway Semin Oncol 2006, 33 392-406
9. Cutsem EV, Kohne CH, Hitre E, et al.: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Eng J Med 2009, 360 1408-1417.
10. Andreyev HJ, Norman AR, Cunningham D, et al.: Kirsten ras mutations in patients with colorectal cancer the multicenter "RASCAL" study J Natl Cancer Inst 1998, 90(9) 675-684
11. Andreyev HJ, Norman AR, Cunningham D, et al.: Kirsten ras mutations in patients with colorectal cancer the 'RASCAL 11' study. Br J Cancer 2001, 85(5) 692-696
12. Bokemeyer C, Bondarenko I, Hartman J.T., et al.: Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer the OPUS study Ann Oncol 2011, 22 1535-1546
13. Amado RG, Wolf M, Peeters M., et al.: Wild-type KRAS is required for pamtumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 2008, 26 1626-1634
14. Hurwitz HI, Yi J, Ince W., et al.: The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer Oncologist 2009, 14(1) 22-28
15. Westra JL, Schaapveld M, Hollema H., et al.: Determination of TP53 mutation is more relevant that microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients J Clin Oncol 2005; 23:5635-5643
16. Roth A, Tejpar S, Delorenzi M., et al.: Prognostic role of KRAS and BRAF in stage II and III resected colon cancer results of the translational study on the PETACC-3, EORTC 40933, SAKK 60-00 trial. J Clin Oncol 2009, 28. 466-474
17. Cerottini JP, Caplin S, Saraga E., et al.: The type of K-ras mutation determines prognosis in colorectal cancer. Am J Surg 1998; 175(3)198-202.
18. Stec R, Bodnar L, Charkiewicz R., et al.: K-Ras gene mutation status as a prognostic and predictive factor in patients with colorectal cancer undergoing irinotecanor oxahplatinbased chemotherapy Cancer Biol Ther 2012; 13(13);1235-1243
19. Douillard JY, Siena S, Cassidy J., et al.: Phase III trial of panitumumab with infusional fluorouracil, leucovorm, and oxahplatin [F0LF0X4] versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer the PRIME study J Clin Oncol 2010; 28(31). 4697-4705.
20. Diaz-Rubio E, Gomez-Espana A, Massuti B., et al.: Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab a TTD group cooperative study. PLoS One 2012, 7(10). e4735